Health Care Supplies

Rapid Therapeutic Science Laboratories, Inc.

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

MetaVia

Micware

MicroAlgo

BiomX

Tradr 2X Long XNDU Daily ETF

VTVT

TVTX

RTSL

SBIO

LABU

Vector Science & Therapeutics has entered an option agreement to invest up to $1 million for a 15% equity stake in LyoGenesis Plus, which is acquiring MPP Group LLC, an FDA-registered cGMP manufacturing organization. This agreement allows Vector to secure a long-term manufacturing platform for its peptide formulations without the costs of building a facility. The partnership aims to develop 22 novel pharmaceutical-grade peptide formulations, leveraging MPP's capabilities to meet the growing $80.8 billion peptide market.

PR Newswire

vTv Therap

Travere Therapeutics

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Vector Science & Therapeutics has appointed Tommy Thompson, former Governor of Wisconsin and U.S. Secretary of Health and Human Services, as Chairman of the Board. Thompson brings extensive healthcare leadership and policy expertise to the company, which focuses on transdermal drug delivery technology. His experience includes overseeing major healthcare initiatives and advocating for healthcare innovation. CEO Bill Jackson expressed confidence in Thompson's ability to guide the company's strategic direction as it develops breakthrough therapies.

prnewswire

08:12 ETVector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Rapid Dose Therapeutics Corp (TSE:DOSE) announced it will pay the March 31, 2026 interest on its secured convertible notes by issuing 1,263,001 common shares instead of cash, totaling approximately $138,932. This decision reflects the company's reliance on equity financing to manage high-interest debt while preserving cash for operations. The notes, initially part of a $3.1 million private placement, have been extended to November 30, 2026, with an 18% annual interest rate. Analysts rate DOSE stock as a Hold with a price target of C$0.09, citing weak financial performance and elevated risks.

Tip Ranks

Rapid Dose Therapeutics to Pay High-Interest Note Obligations in Shares

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory | RDTCF Stock News

StockTitan

Rapid7

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory | RDTCF Stock News

RPID

As of January 29, 2026, Dose's scientifically endorsed liquid supplements are now being sold at all Perspire Sauna Studio outlets in an effort to enhance customer wellness. This move aims to provide support towards improving guests' health beyond just the sauna experience. Perspire Sauna Studio, recognized as the leading sauna franchise in the nation, offers customers the opportunity to access these supplements to further enhance their wellness routines.

Unusual Whales

SPDR S&P Health Equip

Rapid Micro Biosystems

iShares US Medical Devices

Perspire Sauna Studio partners with Dose to offer liquid supplements at all locations, enhancing post-sauna wellness.

Rapid Therapeutic Science Laboratories, Inc.(RTSL.US)

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

08:12 ETVector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Rapid Dose Therapeutics to Pay High-Interest Note Obligations in Shares

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory | RDTCF Stock News

Perspire Sauna Studio partners with Dose to offer liquid supplements at all locations, enhancing post-sauna wellness.